全球肌萎縮側索硬化症市場：區域分析與預測（2025-2035）

隨著人們對 ALS（肌萎縮側索硬化症）認知的不斷提高、基因研究的進步以及針對 ALS 的藥物開發平臺的不斷擴大，市場不斷成長。

ALS 是一種影響運動神經元的進行進行性神經退化性疾病，隨著科學的進步，治療方法也變得越來越有針對性和有效性。

肌萎縮側索硬化症（ALS）是一種以腦和脊髓運動神經元進行性退化為特徵的疾病，會導致肌肉無力、肢體殘疾，最終導致死亡。隨著對此疾病分子機制的研究不斷深入，創新治療方案層出不窮。因此，ALS治療市場正處於治療方案選擇的重要轉捩點。

市場生命週期階段

ALS 治療市場目前經歷快速演變，從以症狀為中心的治療轉向以改變疾病進展為標靶治療。目前，大多數治療目的是減緩 ALS 的進展並緩解症狀，但致力於該疾病遺傳和分子機制的新干涉方法興起。具體而言，疾病修正治療（DMT）、基因治療和生物製藥等方法有可能顯著改變 ALS 的治療方式。

北美憑藉其完善的醫療基礎設施、較高的診斷率以及對ALS研究的大量投入，預計將繼續佔據全球ALS市場的主要佔有率。隨著大型製藥企業、研究機構和醫療保健提供者致力於該地區ALS治療的進步，預計市場將進一步擴大。

本報告調查了全球肌萎縮側索硬化症市場，並總結了主要趨勢、影響市場的因素分析、法律制度、臨床試驗趨勢、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局和主要企業的概況。

目錄

執行摘要

第1章 全球肌萎縮側索硬化症市場：產業展望

• 市場概況與生態系統
• 肌萎縮側索硬化症的流行病學分析
  • 美國
  • 歐盟5國
• 市場趨勢
• 臨床試驗
  • 依階段
• 監理格局分析
  • 美國法律要求與框架
  • 歐盟法律要求和框架
• 市場動態
  • 影響分析
  • 市場促進因素
  • 市場限制
  • 市場機會

第2章 全球肌萎縮側索硬化症市場：依地區

• 北美洲
  • 主要調查結果
  • 市場動態
  • 市場規模及預測
• 歐洲
  • 主要調查結果
  • 市場動態
  • 市場規模及預測
• 亞太地區
  • 主要調查結果
  • 市場動態
  • 市場規模及預測

第3章 全球肌萎縮側索硬化症市場：競爭基準化分析與公司簡介

• 競爭格局
  • 各公司主要策略及發展
  • 主要發展分析
• 公司簡介
  • Mitsubishi Tanabe Pharma Corporation
  • Biogen Inc.
  • Aquestive Therapeutics, Inc.
  • Ionis Pharmaceuticals
  • MediciNova
  • AB Science
  • Brainstorm-Cell Therapeutics
  • Italfarmaco SpA

第4章 調查方法

Global Amyotrophic Lateral Sclerosis Market: Overview

The increasing awareness of ALS, advancements in genetic research, and a growing pipeline of therapeutic drugs targeting ALS are driving the market's growth. ALS is a progressive neurodegenerative disease affecting motor neurons, and with the advancements in science, the treatment landscape is becoming increasingly targeted and effective.

Amyotrophic lateral sclerosis is characterized by the progressive degeneration of motor neurons in the brain and spinal cord, leading to muscle weakness, disability, and eventually, death. With significant research efforts aimed at understanding its molecular mechanisms, innovative therapeutic solutions are emerging. As a result, the amyotrophic lateral sclerosis market is on the cusp of a breakthrough in terms of treatment options.

Market Lifecycle Stage

The market for amyotrophic lateral sclerosis treatments is in a rapidly evolving phase, shifting from symptomatic management toward more targeted therapies aimed at modifying the disease progression. While current treatments mainly focus on slowing the progression of amyotrophic lateral sclerosis and providing symptomatic relief, newer interventions are beginning to explore the genetic and molecular mechanisms underlying the disease. Disease-modifying therapies (DMTs), gene therapies, and biologic agents hold the potential to significantly alter the treatment landscape for amyotrophic lateral sclerosis patients.

North America is expected to maintain its dominant position in the global amyotrophic lateral sclerosis market, driven by a well-established healthcare infrastructure, a high rate of diagnosis, and substantial investment in amyotrophic lateral sclerosis research. Major pharmaceutical companies, research institutions, and healthcare providers are focused on advancing treatment options for amyotrophic lateral sclerosis in the region, which is expected to drive further market expansion.

Demand - Drivers and Limitations

The global amyotrophic lateral sclerosis market is driven by several key factors:

• Rising prevalence of amyotrophic lateral sclerosis cases will drive market demand
• Advances in genetic research, coupled with improved understanding of the molecular mechanisms involved in amyotrophic lateral sclerosis
• An increase in clinical trials and investments will accelerate the development of innovative treatments for amyotrophic lateral sclerosis

Limitations:

• The high cost of amyotrophic lateral sclerosis treatments may limit accessibility and market growth
• Lack of awareness in emerging markets will hinder the adoption of amyotrophic lateral sclerosis treatments

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: This report provides valuable insights for pharmaceutical companies and biotech firms looking to develop new amyotrophic lateral sclerosis treatments, focusing on genetic therapies, precision medicine, and biologics that target amyotrophic lateral sclerosis-specific molecular pathways. It helps identify emerging trends and the potential for breakthrough therapies that can modify disease progression.

Competitive Strategy: Pharmaceutical companies and healthcare providers can use the information in this report to evaluate the current competitive landscape, assess market trends, and develop strategies that ensure long-term success in the global amyotrophic lateral sclerosis Market. Understanding the major players, new entrants, and their strategies will help companies stay ahead of the competition.

Key Market Players and Competition Synopsis

The companies profiled in this report are selected based on expert insights, evaluating company coverage, product portfolio, and market penetration. Leading players in the global amyotrophic lateral sclerosis market include pharmaceutical companies who hold substantial shares of the market.

Some of the prominent names established in this market are:

• Mitsubishi Tanabe Pharma Corporation
• Biogen Inc.
• Aquestive Therapeutics, Inc.
• Ionis Pharmaceuticals
• MediciNova
• AB Science
• Brainstorm-Cell Therapeutics
• Italfarmaco S.p.A.

Table of Contents

Executive Summary

Scope of Study

Definition

Inclusion and Exclusion Criteria

1. Global Amyotrophic Lateral Sclerosis Market: Industry Outlook

• 1.1 Market Overview and Ecosystem
• 1.2 Epidemiological Analysis of Amyotrophic Lateral Sclerosis
  • 1.2.1 U.S.
  • 1.2.2 EU5
• 1.3 Market Trends
• 1.4 Clinical Trials
  • 1.4.1 By Phase
• 1.5 Regulatory Landscape Analysis
  • 1.5.1 Legal Requirement and Framework in U.S.
  • 1.5.2 Legal Requirement and Framework in E.U.
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraints
  • 1.6.4 Market Opportunities

2. Global Amyotrophic Lateral Sclerosis Market, by Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Key Findings
  • 2.1.2 Market Dynamics
  • 2.1.3 Market Sizing and Forecast
    • 2.1.3.1 North America Amyotrophic Lateral Sclerosis Market (by Country)
      • 2.1.3.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Key Findings
  • 2.2.2 Market Dynamics
  • 2.2.3 Market Sizing and Forecast
    • 2.2.3.1 Europe Amyotrophic Lateral Sclerosis Market (by Country)
      • 2.2.3.1.1 Germany
      • 2.2.3.1.2 France
      • 2.2.3.1.3 Italy
      • 2.2.3.1.4 U.K.
• 2.3 Asia-Pacific
  • 2.3.1 Key Findings
  • 2.3.2 Market Dynamics
  • 2.3.3 Market Sizing and Forecast
    • 2.3.3.1 Asia-Pacific Amyotrophic Lateral Sclerosis Market (by Country)
      • 2.3.3.1.1 Japan

3. Global Amyotrophic Lateral Sclerosis Market - Competitive Benchmarking and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Key Strategies and Developments by Company
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 Mergers and Acquisitions
    • 3.1.1.3 Regulatory Approvals
    • 3.1.1.4 Partnerships, Collaborations and Business Expansions
  • 3.1.2 Key Developments Analysis
• 3.2 Company Profiles
  • 3.2.1 Mitsubishi Tanabe Pharma Corporation
    • 3.2.1.1 Company Overview
    • 3.2.1.2 Product Portfolio
    • 3.2.1.3 Target Customers/End Users
    • 3.2.1.4 Key Personnels
    • 3.2.1.5 Analyst View
  • 3.2.2 Biogen Inc.
    • 3.2.2.1 Company Overview
    • 3.2.2.2 Product Portfolio
    • 3.2.2.3 Target Customers / End Users
    • 3.2.2.4 Key Personnels
    • 3.2.2.5 Analyst View
  • 3.2.3 Aquestive Therapeutics, Inc.
    • 3.2.3.1 Company Overview
    • 3.2.3.2 Product Portfolio
    • 3.2.3.3 Target Customers / End Users
    • 3.2.3.4 Key Personnels
    • 3.2.3.5 Analyst View
  • 3.2.4 Ionis Pharmaceuticals
    • 3.2.4.1 Company Overview
    • 3.2.4.2 Product Portfolio
    • 3.2.4.3 Target Customers / End Users
    • 3.2.4.4 Key Personnels
    • 3.2.4.5 Analyst View
  • 3.2.5 MediciNova
    • 3.2.5.1 Company Overview
    • 3.2.5.2 Product Portfolio
    • 3.2.5.3 Target Customers / End Users
    • 3.2.5.4 Key Personnels
    • 3.2.5.5 Analyst View
  • 3.2.6 AB Science
    • 3.2.6.1 Company Overview
    • 3.2.6.2 Product Portfolio
    • 3.2.6.3 Target Customers / End Users
    • 3.2.6.4 Key Personnels
    • 3.2.6.5 Analyst View
  • 3.2.7 Brainstorm-Cell Therapeutics
    • 3.2.7.1 Company Overview
    • 3.2.7.2 Product Portfolio
    • 3.2.7.3 Target Customers / End Users
    • 3.2.7.4 Key Personnels
    • 3.2.7.5 Analyst View
  • 3.2.8 Italfarmaco S.p.A.
    • 3.2.8.1 Company Overview
    • 3.2.8.2 Product Portfolio
    • 3.2.8.3 Target Customers / End Users
    • 3.2.8.4 Key Personnels
    • 3.2.8.5 Analyst View

4. Research Methodology

List of Figures

• Figure: Global Amyotrophic Lateral Sclerosis Market, Coverage
• Figure: Global Amyotrophic Lateral Sclerosis Market, Key Trends, Impact Analysis
• Figure: Global Amyotrophic Lateral Sclerosis Market, Competitive Landscape, January 2022- April 2025

List of Tables

• Table: Global Amyotrophic Lateral Sclerosis Market, Dynamics and Impact Analysis
• Table: Global Amyotrophic Lateral Sclerosis Market, Regulatory Landscape
• Table: Global Amyotrophic Lateral Sclerosis Market, (by Region), $Million, 2023-2035